Retatrutide for prediabetes — 6 essential facts.

Retatrutide for prediabetes is a topic where genuine, encouraging evidence exists — just not quite where most people assume. While no dedicated retatrutide trial has studied prediabetes specifically, the broader GLP-1 medication class has produced some of the most compelling prediabetes reversal data in modern metabolic medicine.

This guide explains what prediabetes actually is, what already-approved GLP-1 medications have proven in dedicated prediabetes trials, what retatrutide’s own trial data shows in the closely related area of type 2 diabetes, and where the genuine evidence gap sits. This is educational content — retatrutide is not an approved medicine, and nothing here constitutes medical advice. General information on prediabetes is available through the NHS.

Retatrutide for prediabetes — fact 1: what prediabetes is

Prediabetes, also called non-diabetic hyperglycaemia, describes blood glucose levels higher than normal but below the threshold for a type 2 diabetes diagnosis — typically an HbA1c of 6.0 to 6.4%, or fasting plasma glucose of 100 to 125 mg/dL. It affects an estimated 6 to 9% of adults globally.

Prediabetes is not a mild or inconsequential finding. It carries a significantly elevated risk of progressing to full type 2 diabetes, and is independently associated with increased cardiovascular risk even before that progression occurs. This is precisely why interest in retatrutide for prediabetes has grown — early, effective intervention has real, long-term value.

Retatrutide for prediabetes — fact 2: what STEP 10 proved

The strongest, most directly relevant evidence in this entire conversation actually comes from semaglutide, not retatrutide. The STEP 10 trial was a dedicated, randomised, placebo-controlled Phase 3 trial conducted specifically in adults with obesity and prediabetes — not type 2 diabetes — across sites in Canada, Denmark, Finland, Spain, and the UK.

The results were striking: 52 weeks of once-weekly semaglutide 2.4mg achieved an 81% prediabetes remission rate, compared to just 14% with lifestyle intervention alone — combined with over 11% greater average weight loss. Pooled data from the earlier STEP 1, 3, and 4 trials similarly found 84.1% of participants with baseline prediabetes achieved normoglycaemia at 68 weeks on semaglutide, compared to 47.8% on placebo.

Retatrutide for prediabetes — fact 3: retatrutide’s diabetes results

While no dedicated prediabetes trial for retatrutide exists, its results in the closely related area of established type 2 diabetes are genuinely striking. The TRANSCEND-T2D-1 trial, involving 537 adults with type 2 diabetes and a mean disease duration of 2.5 years, found HbA1c reductions of up to 2.0 percentage points and weight loss of up to 16.8% at 40 weeks — reported at the 2026 ADA Scientific Sessions and published simultaneously in The Lancet.

For context, this compares to a 0.81 percentage point HbA1c reduction in the placebo group in the same trial — meaning retatrutide’s effect was more than double the placebo response, and researchers described these findings as supporting retatrutide’s use as monotherapy for early type 2 diabetes.

Retatrutide for prediabetes — fact 4: the honest evidence gap

This is the crux of the retatrutide for prediabetes question. Retatrutide has demonstrated exceptionally strong glycaemic and weight loss results in adults who already have type 2 diabetes. Semaglutide has demonstrated exceptionally strong prediabetes remission results in adults with prediabetes specifically. What does not yet exist is a trial connecting these two — retatrutide, studied specifically in a prediabetes population.

Given that retatrutide’s weight loss and glycaemic results in every population studied so far have generally matched or exceeded semaglutide’s, it is a reasonable, evidence-informed expectation that retatrutide would perform at least comparably well in prediabetes specifically. But “reasonable expectation” is not the same as “proven finding,” and this distinction matters.

Retatrutide for prediabetes — why a dedicated trial matters

It might seem reasonable to assume that a medication proven effective in type 2 diabetes would automatically work at least as well in prediabetes, given that prediabetes is a milder version of the same underlying glucose dysregulation. In practice, dedicated prediabetes trials matter because the population, goals, and even the definition of success differ meaningfully from diabetes trials.

In established type 2 diabetes trials, success is typically measured as HbA1c reduction from an already-elevated baseline. In prediabetes trials like STEP 10, success is measured as complete remission back to normal glucose regulation — a different and, in some ways, a more demanding target. A medication highly effective at lowering already-high blood sugar does not automatically guarantee it can return borderline-elevated blood sugar all the way to normal in every case, which is precisely why regulatory bodies and researchers require separate trials for each population rather than assuming results transfer automatically.

Retatrutide for prediabetes — fact 5: why weight loss magnitude matters

The Diabetes Prevention Program, a landmark study in this field, found that lifestyle intervention producing at least 7% weight loss, combined with 150 minutes of weekly physical activity, significantly reduced progression from prediabetes to type 2 diabetes. This established the general principle that weight loss magnitude directly predicts prediabetes reversal likelihood.

Retatrutide’s trials have consistently produced weight loss in the 20 to 30% range — several multiples beyond the 7% threshold shown to meaningfully reduce diabetes progression through lifestyle change alone. If this same dose-response relationship between weight loss magnitude and glycaemic normalisation holds for retatrutide as it has for semaglutide, the theoretical case for strong prediabetes benefit is compelling, even without a dedicated trial confirming it yet.

Retatrutide for prediabetes — fact 6: what to do today

For anyone with prediabetes right now, waiting years for retatrutide’s eventual approval is a genuine consideration worth discussing carefully, particularly given that an already-approved option with dedicated, published prediabetes remission data — semaglutide — exists today.

• Untreated prediabetes can progress during any waiting period, so the time value of starting effective treatment now is a real factor.
• Semaglutide’s STEP 10 data provides a proven, published pathway with real remission rates specific to prediabetes.
• Lifestyle intervention remains valuable regardless of medication choice, and the Diabetes Prevention Program’s findings apply alongside any pharmacological approach.
• Discuss your specific HbA1c and risk profile with a healthcare provider to determine the most appropriate current pathway for your situation.

For more on retatrutide’s current status, read our guide on retatrutide’s regulatory status and our overview of retatrutide and insulin resistance. Explore our Mounjaro product page for an approved option available today, or read patient reviews.

Prediabetes is, in many respects, the single best-timed opportunity in metabolic health — a stage where meaningful intervention can still prevent a lifelong diabetes diagnosis entirely. Whichever medication or approach ultimately proves most effective, the underlying message remains the same: earlier action produces meaningfully better long-term outcomes than waiting and monitoring alone.